Investigational drug · Phase 3
YZJ-1139
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Insomnia Disorder.
Phase 3Last checked: Nov 20, 2026Latest source record: Jun 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
9
Any phase or sponsor naming "YZJ-1139"
First trial start
2025
Mar 25, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "YZJ-1139", any sponsor or status.
Conditions studied
As listed on its trial records.
- Insomnia Disorder
Approved drugs for the same conditions: Insomnia · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "YZJ-1139" as an intervention, largest first.
- Safety and Efficacy Study of YZJ-1139 in Insomnia DisorderPivotal-lookingCompleted
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.Industry
NCT05525637 · 1,037 participants · Start Dec 17, 2021 · Primary completion Jul 7, 2023
Drug: YZJ-1139 20mg; YZJ-1139 40mg and 1 more · For: Insomnia Disorder
Sites: Beijing, China; Bengbu, China; Binzhou, China · 83 sites in all
- Safety and Efficacy Study of YZJ-1139 in Primary Chronic Insomnia DisorderPivotal-lookingCompleted
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.Industry
NCT06680505 · 300 participants · Start Aug 4, 2019 · Primary completion Sep 30, 2020
Drug: YZJ-1139 10mg; YZJ-1139 20mg and 3 more · For: Insomnia Disorder
Sites: Beijing, China; Bengbu, China; Changchun, China · 33 sites in all
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of YZJ-1139 in Healthy ParticipantsPivotal-lookingCompleted
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.Industry
NCT06673927 · 104 participants · Start Dec 1, 2017 · Primary completion Nov 21, 2018
Drug: YZJ-1139; YZJ-1139 and 1 more · For: Insomnia
Sites: Beijing, China
- Safety and Efficacy Study of YZJ-1139 Tablets in Insomnia DisorderPivotal-lookingCompleted
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.Industry
NCT06975514 · 61 participants · Start Mar 25, 2025 · Primary completion Jul 21, 2025
Drug: YZJ-1139; Zolpidem · For: Insomnia Disorder
Sites: Beijing, China; Chengdu, China; Chongqing, China · 16 sites in all
- A Drug-drug Interaction Study of YZJ-1139 Tablets and Ticagrelor Tablets in Healthy SubjectsCompleted
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.Industry
NCT06671470 · 27 participants · Start Aug 22, 2024 · Primary completion Sep 13, 2024
Drug: YZJ-1139 tablets; Ticagrelor Tablets · For: Insomnia
Sites: Huangzhou, China
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.Industry
NCT06680531 · 24 participants · Start Aug 31, 2024 · Primary completion Sep 19, 2024
Drug: YZJ-1139 tablets; Escitalopram oxalate tablets and 1 more · For: Insomnia; Central Nervous System
Sites: Guangzhou, China
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.Industry
NCT06671509 · 24 participants · Start Mar 22, 2024 · Primary completion Apr 18, 2024
Drug: YZJ-1139 · For: Insomnia; Hepatic Impairment
Sites: Changchun, China
- PK/PD Study of YZJ-1139Completed
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.Industry
NCT06685341 · 20 participants · Start Mar 7, 2019 · Primary completion Apr 10, 2019
Drug: YZJ-1139; Placebo and 1 more · For: Insomnia
Sites: Beijing, China
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.Industry
NCT06671444 · 16 participants · Start Jun 3, 2024 · Primary completion Oct 11, 2024
Drug: YZJ-1139 · For: Insomnia; Renal Impairment
Sites: Nanjing, China; Bengbu, China; Xuzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- Single-dose pharmacokinetics, tolerability, and physiologically based pharmacokinetic modeling of Fazamorexant in Chinese patients with hepatic impairment and in healthy controls.
Li Q, Wu M, Li C, et al. · Front Pharmacol 2026
Also in development for Insomnia Disorder
- HS-10506Phase 32 trials
Jiangsu Hansoh Pharmaceutical Co., Ltd. · Insomnia Disorder
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.